Plain-English translation of NCT05549661 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to treat certain blood cancers—specifically chronic myelomonocytic leukemia and related conditions—in patients whose disease has not responded to or has returned after standard treatments. works by blocking a protein called PLK1 that helps cancer cells divide. Researchers want to learn whether this medication is safe and whether it can help shrink the cancer or put it into remission.
People with these blood cancers often run out of treatment options when standard therapies like hydroxyurea or chemotherapy stop working. This medication targets a different pathway in cancer cells, offering hope for patients who have few alternatives left.
You likely qualify if…
You likely don't qualify if…
You will take by mouth once a day for as long as the medication is helping you and you tolerate it well. You'll have regular visits to the clinic for blood tests, physical exams, and ultrasounds to check if your spleen has shrunk. You'll also have bone marrow biopsies at the start and during the trial so doctors can see how your cancer cells are responding. The study team will closely monitor you for side effects and watch your vital signs and heart function throughout.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States